🔎 Trials Near Me

Home › Medulloblastoma › Florida

Medulloblastoma clinical trials in Florida

6 studies for Medulloblastoma are looking for participants at sites in Florida.

Cities in Florida

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

  • Orlando Health Arnold Palmer Hospital for Children, Orlando
  • St. Joseph's Children's Hospital, Tampa
RecruitingPhase 2
59 Months · All sexes · Updated Sep 15, 2026 · NCT05535166

Digoxin Medulloblastoma Study

  • Nemours Jacksonville, Jacksonville
  • University of Miami, Miami
  • Johns Hopkins All Children's, St. Petersburg
  • and 1 more
RecruitingPhase 2
12 Months – 30 Years · All sexes · Updated Aug 26, 2026 · NCT06701812

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

  • Golisano Children's Hospital of Southwest Florida, Fort Myers
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood
  • Nemours Children's Clinic-Jacksonville, Jacksonville
  • and 7 more
RecruitingPhase 3
Ages 4 to 21 · All sexes · Updated Aug 25, 2026 · NCT05382338

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  • Nicklaus Children's Hospital, Miami
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

  • Nicklaus Children's Hospital, Miami
  • Arnold Palmer Hospital for Children, Orlando
  • All Children's Hospital Johns Hopkins Medicine, St. Petersburg
  • and 1 more
RecruitingPhase 2
Up to age 21 · All sexes · Updated Aug 12, 2026 · NCT04696029

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

  • University of Florida Health, Gainesville
RecruitingPhase 1
Ages 4 to 30 · All sexes · Updated Aug 7, 2026 · NCT06514898

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.